Elevated circulating alpha-klotho by angiotensin II receptor blocker losartan is associated with reduction of albuminuria in type 2 diabetic patients

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 15, Issue 4, 2014, Pages 487-490

  Lim, Su Chi ^a   Liu, Jian Jun ^a   Subramaniam, Tavintharan ^a   Sum, Chee Fang ^a  

^a KHOO TECK PUAT HOSPITAL   (Singapore)

Author keywords

angiotensin receptor 1 blocker; diabetes; losartan; klotho

Indexed keywords

ALBUMIN; ALPHA KLOTHO PROTEIN; CHOLESTEROL; CREATININE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; KLOTHO PROTEIN; LOSARTAN; LOW DENSITY LIPOPROTEIN; POTASSIUM; QUINAPRIL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA GLUCURONIDASE; TETRAHYDROISOQUINOLINE DERIVATIVE;

ADULT; ALBUMINURIA; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE URINE LEVEL; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DRUG ANTAGONISM; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POST HOC ANALYSIS; POTASSIUM BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; MIDDLE AGED;

ALBUMINURIA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; GLUCURONIDASE; HUMANS; LOSARTAN; MALE; MIDDLE AGED; TETRAHYDROISOQUINOLINES;

EID: 84887305819     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320313475905     Document Type: Article

References (23)

1. Bjorklund P, Krajisnik T, Akerstrom G, et al. Type I membrane klotho expression is decreased and inversely correlated to serum calcium in primary hyperparathyroidism. J Clin Endocrinol Metab. 2008 ; 93: 4152-4157
2. Chihara Y, Rakugi H, Ishikawa K, et al. Klotho protein promotes adipocyte differentiation. Endocrinology. 2006 ; 147: 3835-3842
3. Donate-Correa J, Mora-Fernandez C, Martinez-Sanz R, et al. Expression of FGF23/KLOTHO system in human vascular tissue. Int J Cardiol. 2011 ;:
4. Chen CD, Podvin S, Gillespie E, et al. Insulin stimulates the cleavage and release of the extracellular domain of Klotho by ADAM10 and ADAM17. Proc Natl Acad Sci U S A. 2007 ; 104: 19796-19801
5. Imura A, Iwano A, Tohyama O, et al. Secreted Klotho protein in sera and CSF: implication for post-translational cleavage in release of Klotho protein from cell membrane. FEBS Lett. 2004 ; 565: 143-147
6. Hu MC, Kuro-o M, Moe OW. Klotho and kidney disease. J Nephrol. 2010 ; 23: S136-144
7. John GB, Cheng CY, Kuro-o M. Role of Klotho in aging, phosphate metabolism, and CKD. Am J Kidney Dis. 2011 ; 58: 127-134
8. Bernheim J, Benchetrit S. The potential roles of FGF23 and Klotho in the prognosis of renal and cardiovascular diseases. Nephrol Dial Transplant. 2011 ; 26: 2433-2438
9. Saito K, Ishizaka N, Mitani H, et al. Iron chelation and a free radical scavenger suppress angiotensin II-induced downregulation of klotho, an anti-aging gene, in rat. FEBS Lett. 2003 ; 551: 58-62
10. Yoon HE, Ghee JY, Piao S, et al. Angiotensin II blockade upregulates the expression of Klotho, the anti-ageing gene, in an experimental model of chronic cyclosporine nephropathy. Nephrol Dial Transplant. 2011 ; 26: 800-813
11. Haller H, Ito S, Izzo JL, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011 ; 364: 907-917
12. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001 ; 345: 851-860
13. Lim SC, Koh AF, Goh SK, et al. Angiotensin receptorantagonist vs. angiotensin-converting enzyme inhibitor in Asian subjects with type 2 diabetes and albuminuria - a randomized crossover study. Diabetes Obes Metab. 2007 ; 9: 477-482
14. Komaba H, Koizumi M, Tanaka H, et al. Effects of cinacalcet treatment on serum soluble Klotho levels in haemodialysis patients with secondary hyperparathyroidism. Nephrol Dial Transplant. 2012 ; 27: 1967-1969
15. Yamazaki Y, Imura A, Urakawa I, et al. Establishment of sandwich ELISA for soluble alpha-Klotho measurement: Age-dependent change of soluble alpha-Klotho levels in healthy subjects. Biochem Biophys Res Commun. 2010 ; 398: 513-518
16. Hu MC, Shi M, Zhang J, et al. Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol. 2011 ; 22: 124-136
17. Haruna Y, Kashihara N, Satoh M, et al. Amelioration of progressive renal injury by genetic manipulation of Klotho gene. Proc Natl Acad Sci U S A. 2007 ; 104: 2331-2336
18. Mitani H, Ishizaka N, Aizawa T, et al. In vivo klotho gene transfer ameliorates angiotensin II-induced renal damage. Hypertension. 2002 ; 39: 838-843
19. An J, Nakajima T, Kuba K, et al. Losartan inhibits LPS-induced inflammatory signaling through a PPARgamma-dependent mechanism in human THP-1 macrophages. Hypertens Res. 2010 ; 33: 831-835
20. Kamper M, Tsimpoukidi O, Chatzigeorgiou A, et al. The antioxidant effect of angiotensin II receptor blocker, losartan, in streptozotocin-induced diabetic rats. Transl Res. 2010 ; 156: 26-36
21. Moreno JA, Izquierdo MC, Sanchez-Nino MD, et al. The inflammatory cytokines TWEAK and TNFalpha reduce renal klotho expression through NFkappaB. J Am Soc Nephrol. 2011 ; 22: 1315-1325
22. Roson MI, Della Penna SL, Cao G, et al. Different protective actions of losartan and tempol on the renal inflammatory response to acute sodium overload. J Cell Physiol. 2010 ; 224: 41-48
23. Thurston RD, Larmonier CB, Majewski PM, et al. Tumor necrosis factor and interferon-gamma down-regulate Klotho in mice with colitis. Gastroenterology. 2010 ; 138: 1384-1394